ClinicalTrials.gg
CompletedNCT02738970Updated Jun 12, 2018

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

A Phase 1 interventional study of Trastuzumab and Pertuzumab in Early Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 2 sites in New Zealand. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-12.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
59th of 104
88 · median 100
Started
2016
with 5 others
Phase 1
9 of 104
2 open now
Registered
44th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 59th largest by enrollment, is one of 6 that started in 2016, is one of 9 in phase 1, and was the 44th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This study involves a two-part design. Part 1 is designed to determine the optimal dose of subcutaneous (SC) Perjeta, injected alone or mixed with Herceptin, that results in comparable exposure to intravenous (IV) Perjeta. Exposure between SC Perjeta and IV Perjeta will be compared using a compilation of pharmacokinetic (PK) parameters such as area under the concentration-time curve (AUC), maximum serum concentration (Cmax), time of maximum concentration (Tmax), and serum trough concentration (Ctrough). Part 2 is designed to confirm the dosing regimen in women with EBC on the basis of safety, tolerability, and PK assessments.

03

Conditions studied

  • Early Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 1: Healthy male volunteers 18 to 45 years of age
  • Part 1: (LVEF) at least 55 percent (%)
  • Part 1: (BMI) 18 to 32 kilograms per meter-squared (kg/m\^2)
  • Part 1: Normal, intact skin without tattoos or lesions in the injection area
  • Part 2: Females at least 18 years of age
  • Part 2: (ECOG) performance status of 0
  • Part 2: Previously treated, non- carcinoma of the breast
  • Part 2: Baseline LVEF at least 55%
  • Part 2: Negative pregnancy test and use of adequate measures among women of

Exclusion criteria

Exclusion Criteria:

  • Part 1: Positive urine test for drugs of abuse
  • Part 1: History of exposure or active viral infection of , , or (HIV)
  • Part 1: Cardiac disease including hypertension or hypotension
  • Part 1: Lower extremity edema
  • Part 1: Any history of systemic disease
  • Part 1: History of breast cancer
  • Part 1: Chronic use
  • Part 1: Receipt of IV antibiotics within 7 days prior to enrollment
  • Part 2: Concurrent requiring therapy that may interfere with pharmacokinetic investigations, or history of other malignancy within 5 years prior to Screening
  • Part 2: Significant cumulative exposure to anthracyclines
  • Part 2: Serious cardiac disease including uncontrolled hypertension
  • Part 2: Poor hematologic, renal, or hepatic function
  • Part 2: Pregnant or lactating women
  • Part 2: History of exposure or active viral infection of Hepatitis B, hepatitis C, or HIV
  • Part 2: Chronic corticosteroid use
  • Part 2: Receipt of IV antibiotics within 7 days prior to enrollment
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Active comparator
    Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV

    Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 420 mg IV.

    Drug: Pertuzumab

  • Experimental
    Part 1-Cohort 2: Pertuzumab 400 mg SC

    Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC.

    Drug: Pertuzumab

  • Experimental
    Part 1-Cohort 3: Pertuzumab 600 mg SC

    Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 600 mg SC.

    Drug: Pertuzumab

  • Experimental
    Part 1-Cohort 4: Pertuzumab 1200 mg SC

    Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC.

    Drug: Pertuzumab

  • Active comparator
    Part 1-Cohort 5: Trastuzumab 600 mg SC

    Part 1 includes healthy male participants. Participants will receive a single injection of trastuzumab 600 mg SC.

    Drug: Trastuzumab

  • Experimental
    Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC

    Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 400 mg and trastuzumab 600 mg SC.

    Drug: Trastuzumab · Drug: Pertuzumab

  • Experimental
    Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC

    Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC.

    Drug: Trastuzumab · Drug: Pertuzumab

  • Experimental
    Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC

    Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC without recombinant human hyaluronidase (rHuPH20) excipient.

    Drug: Trastuzumab · Drug: Pertuzumab

  • Experimental
    Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC

    Part 2 includes women with early breast cancer. Cohort A will be enrolled only if FDC of pertuzumab and trastuzumab is not feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC administered separately. The dose of pertuzumab will be identified during Part 1.

    Drug: Trastuzumab · Drug: Pertuzumab

  • Experimental
    Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC

    Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1.

    Drug: Trastuzumab · Drug: Pertuzumab

  • Experimental
    Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC

    Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents formulated together and administered in one injection (FDC). The dose of pertuzumab will be identified during Part 1.

    Drug: Trastuzumab · Drug: Pertuzumab

Interventions

  • Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.

    Also known as: Herceptin, RO0452317

  • Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.

    Also known as: Perjeta, RO4368451

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration from Time Zero to Time Infinity (AUC0-inf) of Pertuzumab SC

    Time frame: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)

  2. Maximum Serum Concentration (Cmax) of Pertuzumab SC

    Time frame: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)

  3. Time to Reach Cmax (Tmax) of Pertuzumab SC

    Time frame: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)

  4. Minimum Serum Concentration (Cmin) of Pertuzumab SC

    Time frame: Pre-dose (0 hours) and 6, 8, and 12 hours post-dose on Day 1; on Days 2, 3, 5, 8, 10, 15, 22, 43, 85; and at follow-up visit (up to approximately 24 months)

  5. AUC0-inf of Pertuzumab IV

    Time frame: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)

  6. Cmax of Pertuzumab IV

    Time frame: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)

  7. Tmax of Pertuzumab IV

    Time frame: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)

  8. Cmin of Pertuzumab IV

    Time frame: Pre-dose (0 hours) and 1.5 and 3 hours post-dose on Day 1; on Days 2, 3, 5, 8, 15, 22, 35, 43, 85; and at follow-up visit (up to approximately 24 months)

Secondary outcomes

  1. Percentage of Participants with Adverse Events

    Time frame: Baseline up to approximately 24 months

  2. Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Pertuzumab

    Time frame: Baseline, Day 22, Day 85, and 7 months post-dose (up to approximately 24 months overall)

  3. Percentage of Participants with ATAs to Trastuzumab

    Time frame: Baseline, Day 22, Day 85, and 7 months post-dose (up to approximately 24 months overall)

  4. Percentage of Participants with ATAs to rHuPH20

    Time frame: Baseline, Day 22, Day 85, and 7 months post-dose (up to approximately 24 months overall)

07

Study locations

2 sites
  • Auckland Clinical Studies
    Auckland, 1142, New Zealand
  • Christchurch Clinical Studies Trust
    Christchurch, 8011, New Zealand
08

References and documents

Publications

  • Kirschbrown WP, Wynne C, Kagedal M, Wada R, Li H, Wang B, Nijem I, Badovinac Crnjevic T, Gasser H, Heeson S, Eng-Wong J, Garg A. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study. J Clin Pharmacol. 2019 May;59(5):702-716. doi: 10.1002/jcph.1362. Epub 2018 Dec 19. PubMed 30570763 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in May 2018, 23 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 23 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2016
First posted
Apr 14, 2016
StartActual
Jun 23, 2016
Primary completionActual
May 31, 2018
CompletionActual
May 31, 2018
Last update
Jun 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02738970
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 14, 2016
Start date
Jun 23, 2016
Primary completion
May 31, 2018
Completion
May 31, 2018
Last update
Jun 12, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion